Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17986813 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL18669621 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL23925570 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL29984534 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL15116885 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL30591306 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL18094053 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL18611180 | 0.89 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL30505549 | 0.88 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 | |
| SCHEMBL25286674 | 0.88 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215662-A | Modulators of CCR6 receptors | 爱杜西亚药品有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3858349-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3181570-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-2460806-B1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| CN-102510865-B | Nitrogen-containing spiro compound and pharmaceutical use thereof | JAPAN TOBACCO INC | 2015-04-15 | — | — | CN | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8609647-B2 | Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof | JAPAN TOBACCO INC. (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2460806-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | HSD17B10 2300/4885SMN1; SMN2 1988/4885NR1H2 339/4885 |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NPR1 | HSD17B10 2597/4885SMN1; SMN2 2057/4885NR1H2 850/4885 |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | HSD17B10 2300/4885SMN1; SMN2 1988/4885NR1H2 339/4885 |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, NPR1 | HSD17B10 2549/4885SMN1; SMN2 2018/4885NR1H2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.